Is Ado-trastuzumab emtansine included in medical insurance?

Ado-trastuzumab emtansine is indicated for the treatment of metastatic breast cancer in patients whose tumors overexpress the HER2 protein and who have previously received trastuzumab and a taxane alone or in combination. Appropriate patients include patients who have previously received treatment for metastatic disease or who have experienced disease recurrence during or within 6 months of completing adjuvant therapy.

Before treating with trastuzumab, doctors will select patients based on HER2 protein overexpression or HER2 gene amplification in tumor specimens. Assessment of HER2 protein overexpression and/or HER2 gene amplification should be performed by a laboratory with proven capabilities using a breast cancer-specific test approved by the U.S. Food and Drug Administration (FDA). Do not substitute trastuzumab for trastuzumab. Enmei’s trastuzumab generic drug has been launched in China and has entered the scope of medical insurance. Reimbursement is only available to eligible patients. The reimbursement ratio is different in different regions, and the price after reimbursement may be different.

The original drug of Enmei trastuzumab listed in China is a strictly controlled drug, and the price of 100mg per box may be around 20,000 yuan, which is relatively expensive. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.